GERM vs. LFSC
Compare and contrast key facts about Amplify Treatments, Testing and Advancements ETF (GERM) and F/m Emerald Life Sciences Innovation ETF (LFSC).
GERM and LFSC are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. GERM is a passively managed fund by Amplify that tracks the performance of the Prime Treatments, Testing and Advancements Index. It was launched on Jun 17, 2020. LFSC is an actively managed fund by F/m Investments. It was launched on Oct 30, 2024.
Performance
GERM vs. LFSC - Performance Comparison
Loading graphics...
GERM vs. LFSC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
GERM Amplify Treatments, Testing and Advancements ETF | 0.00% | 0.00% | 0.00% |
LFSC F/m Emerald Life Sciences Innovation ETF | -4.45% | 56.54% | -6.02% |
Returns By Period
GERM
- 1D
- 0.00%
- 1M
- 0.00%
- YTD
- 0.00%
- 6M
- 0.00%
- 1Y
- 0.00%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
LFSC
- 1D
- 6.16%
- 1M
- -3.82%
- YTD
- -4.45%
- 6M
- 17.66%
- 1Y
- 55.83%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
GERM vs. LFSC - Expense Ratio Comparison
GERM has a 0.68% expense ratio, which is higher than LFSC's 0.54% expense ratio.
Return for Risk
GERM vs. LFSC — Risk / Return Rank
GERM
LFSC
GERM vs. LFSC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Amplify Treatments, Testing and Advancements ETF (GERM) and F/m Emerald Life Sciences Innovation ETF (LFSC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Loading graphics...
Sharpe Ratios by Period
| GERM | LFSC | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | — | 1.93 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | — | 0.94 | — |
Dividends
GERM vs. LFSC - Dividend Comparison
Neither GERM nor LFSC has paid dividends to shareholders.
Drawdowns
GERM vs. LFSC - Drawdown Comparison
The maximum GERM drawdown since its inception was 0.00%, smaller than the maximum LFSC drawdown of -29.74%. Use the drawdown chart below to compare losses from any high point for GERM and LFSC.
Loading graphics...
Drawdown Indicators
| GERM | LFSC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | 0.00% | -29.74% | +29.74% |
Max Drawdown (1Y)Largest decline over 1 year | 0.00% | -16.25% | +16.25% |
Current DrawdownCurrent decline from peak | 0.00% | -11.08% | +11.08% |
Average DrawdownAverage peak-to-trough decline | 0.00% | -8.25% | +8.25% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 0.00% | 5.80% | -5.80% |
Volatility
GERM vs. LFSC - Volatility Comparison
The current volatility for Amplify Treatments, Testing and Advancements ETF (GERM) is 0.00%, while F/m Emerald Life Sciences Innovation ETF (LFSC) has a volatility of 10.35%. This indicates that GERM experiences smaller price fluctuations and is considered to be less risky than LFSC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| GERM | LFSC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 0.00% | 10.35% | -10.35% |
Volatility (6M)Calculated over the trailing 6-month period | 0.00% | 19.97% | -19.97% |
Volatility (1Y)Calculated over the trailing 1-year period | 0.00% | 29.24% | -29.24% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 0.00% | 29.31% | -29.31% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 0.00% | 29.31% | -29.31% |